Regulatory Considerations for Controlling Intermediates in Type-II Drug Master Files for the Manufacture of Generic Drug Substances

The company has plans to invest $23 billion during the next five years to expand manufacturing and R&D in the US, which will include seven new facilities.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Lack of skills in the AI realm was a distant second among those surveyed about the biggest barrier to innovation while using the technology.

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Advanced solutions are improving drug dissolution, absorption, and overall therapeutic performance.

3D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.